Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SPN-817 Formulations in Healthy Adults
NCT05102552Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Huperzine A in epilepsy (2 cohorts), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Relative Bioavailability at 22 days. Started Oct 2021; status: completed.
02
Drugs
Huperzine A
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05102552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102552.